2026
AP601 achieved First Patient In in its Phase I clinical trial in Australia IBI302 Phase III clinical trial met its primary endpoint
2025
AP402: A Phase I clinical trial targeting HER2-positive tumors began dosing patients in Australia in April. AP601 receives IND clearance from TGA and HREC to initiate First-in-Human Phase I trial in Australia
2024
Series D round of $38 Million was closed AP402 was approved by TGA and HREC to initiate its first-in-human Phase 1/2 trial in Australia
2023
Listed on the Emerging Stock Market Initiation of patient enrollment for Phase III trial of IBI302 for nAMD, originated by AP Bio and licensed to Innovent Patient enrollment started for the Phase I trial of AP505/B1962 which was licensed to Tasly Pharmaceutical Group for China right APBio listed on TPEx Emerging Stock Board (6945.TW) Enrollment of the first patient for Phase I trial of AP203
2022
2020
2019
6945.TW
05.11 2026
Delos and AP Bio Launch Collaboration
Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies
03.30 2026
AP Biosciences, Tasly Amended Collaboration on AP505 (B1962) Out-Licensing
AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)
03.24 2026
IBI302 Meets Primary Endpoint in Pivotal Phase III
IBI302 Meets Primary Endpoint in Pivotal Phase III, Demonstrating First-in-Class Anti-VEGF / Anti-Complement Breakthrough
09.05 2025
AP Biosciences Featured in PharmaBoardroom Interview
Showcasing Vision for Innovative Antibody Drugs
08.28 2025
Australian Expert Dr. Morris Shares AP402 Trial Progress
AP Biosciences Strengthens Taiwan–Australia Clinical Collaboration
建議您使用以下瀏覽器觀看本網站，以獲得最佳瀏覽效果。
